Skip Navigation



JAC Advance Access published online on May 26, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh276
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/1/95    most recent
dkh276v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Steward, J.
Right arrow Articles by Brooks, T. J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steward, J.
Right arrow Articles by Brooks, T. J. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received June 30, 2003
Revised April 2, 2004
Accepted April 14, 2004

Original article

Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones

J. Steward 1*, M. S. Lever 1, A. J. H. Simpson 2, A. M. Sefton 3, T. J. G. Brooks 1 {dagger}

1 Biomedical Sciences, Dstl Porton Down, Salisbury, Wiltshire SP4 OJQ, London, UK
2 Biomedical Sciences, Dstl Porton Down, Salisbury, Wiltshire SP4 OJQ, Department of Medical Microbiology, Royal Free and University College Medical School, University College London, London, UK
3 Department of Medical Microbiology, Barts and the London, Queen Mary's School of Medicine & Dentistry, London, UK

* To whom correspondence should be addressed. E-mail: jasteward{at}dstl.gov.uk.


  Abstract

Objectives: To compare the fluoroquinolones gatifloxacin and moxifloxacin with ciprofloxacin for post-exposure prophylaxis of systemic anthrax in a BALB/c mouse model.

Methods: Treated mice and controls were inoculated subcutaneously with 5x104 spores/mouse of Bacillus anthracis Ames strain and observed for 37 days after challenge. Treated mice were given 100 mg/kg of antibiotic orally twice daily for 14 days, starting at various times post-challenge.

Results: Treatment starting 6 h post-challenge resulted in survival rates of 90%, 15% and 40% for gatifloxacin, moxifloxacin and ciprofloxacin, respectively. Treatment commencing 24 h post-challenge resulted in survival rates of 65%, 10% and 5%, respectively. Treatment starting more than 24 h after exposure had little effect on survival.

Conclusions: Gatifloxacin appeared to be more effective than moxifloxacin or ciprofloxacin, at similar doses, for early post-exposure treatment of murine systemic anthrax. However, these results might be due to differences in potency or pharmacokinetic properties.

Key Words: Keywords: Bacillus anthracis, quinolones, murine model, therapy

{dagger}Present address. HPA Porton Down, Salisbury, Wiltshire SP4 OJG, UK.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
T. Piercy, J. Steward, M. S. Lever, and T. J. G. Brooks
In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice
J. Antimicrob. Chemother., December 1, 2005; 56(6): 1069 - 1073.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Steward, T. Piercy, M. S. Lever, M. Nelson, A. J. H. Simpson, and T. J. G. Brooks
Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection
J. Antimicrob. Chemother., April 1, 2005; 55(4): 523 - 527.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.